Hospital Corporation of America's Sarah Cannon in Nashville, Tenn., a cancer institute, is merging with Cambridge, Mass.-based Genospace, a cloud-based software company focused on advancing personalized medicine.
As per the merger, Sarah Cannon and Genospace will use molecular profiling data to more effectively match cancer patients to new therapies in clinical trials. Genospace will offers its precision medicine platform and enhance it to allow analysis of disparate data from clinical and laboratory sources. The technology will be integrated into Sarah Cannon's network of oncology programs across the United States and United Kingdom.
Additionally, Genospace's platform provides patient-facing portals and disease-specific communities for patient education.
"Bringing together the expertise of Sarah Cannon's physicians coupled with our leadership in molecular data integration and interpretation, we can impact the lives of hundreds of thousands of patients," said Mick Correll, CEO at Genospace.